Enzymotec announced that it has filed a registration statement on Form F-1 with the Securities and Exchange Commission for a proposed initial public offering of shares of its ordinary shares. Enzymotec has applied to list its ordinary shares on the Nasdaq Global Market under the ticker symbol “ENZY.” BofA Merrill Lynch and Jefferies LLC will act as joint book-running managers for the proposed offering. Wells Fargo Securities, LLC will act as lead manager for the proposed offering. Canaccord Genuity and Wedbush Securities will act as co-managers for the proposed offering. Enzymotec develops and manufactures nutritional ingredients and medical foods that provide key ingredients for use in infant formula and nutritional supplements, as well as branded medical foods. The company’s products including bio-functional, lipid-based compounds that address a wide spectrum of growing consumer demands, such as optimal development, supplementation for nutritional deficiencies and needs, and the management of medical disorders and diseases.